Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. BERREBEH (Le Kremlin-Bicêtre, France), R. Thuillet (Le Kremlin-Bicêtre, France), L. Tu (Le Kremlin-Bicêtre, France), B. Le Vely (Le Kremlin-Bicêtre, France), A. Cumont (Le Kremlin-Bicêtre, France), I. Anegon (Nantes, France), A. Huertas (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France), S. Bailly (Grenoble, France), C. Guignabert (Le Kremlin-Bicêtre, France). Loss of Bmp9 does not lead to spontaneous pulmonary hypertension, but attenuates vascular remodeling in experimental models. 3558

Member's Comments

No comment yet.

Related content which might interest you: 2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Vascular reverse remodeling in the mouse model of hypoxia-induced pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 R-Crizotinib predisposes to and exacerbates pulmonary arterial hypertension in animal models Source: Eur Respir J, 57 (5) 2003271; 10.1183/13993003.03271-2020 Year: 2021 In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Targeted gene delivery of BMPR2 attenuates pulmonary hypertension Source: Eur Respir J 2012; 39: 329-343 Year: 2012 Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats Source: Eur Respir J 2011; 37: 1104-1118 Year: 2011 Potential contribution of precursor cells to vascular remodeling in the AdTGF-β1 model of lung fibrosis and pulmonary hypertension Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Involvement of FHL1 in vascular remodelling Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 TSC1/mTOR pathway promotes hypoxia-induced pulmonary hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Renal denervation reduces pulmonary vascular remodeling in two experimental pulmonary arterial hypertension models Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Progression of endothelial dysfunction in relationship with development of pathomorphological changes in monocrotalin-induced model pulmonary hypertension in rats Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 Reduction of endogenous acetylcholine contributes to pulmonary inflammation in a model of emphysema in mice Source: Annual Congress 2012 - The many roads to lung injury Year: 2012 Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects Source: Eur Respir J, 50 (2) 1602337; 10.1183/13993003.02337-2016 Year: 2017